Autolus Therapeutics Projects 2026 AUCATZYL Revenue of at Least $150 Million
Autolus Therapeutics (AUTL) reported Q3 2026 progress driven by the commercialization of its product, AUCATZYL. The company achieved $41.2 million in net revenues for AUCATZYL during the quarter and noted that center onboarding is currently ahead of schedule, with 90 centers already active. Looking forward, management expects full-year 2026 net product revenue for AUCATZYL to meet or exceed $150 million. However, investors should note a shift in clinical timelines, as data from the BOBCAT study is now expected in October 2027.
Tickers: $AUTL
Topics: commercialization progress net revenue quarterly earnings